- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02307903
Evaluation of Quality of Care - Haemodialysis Public-Private-Partnership, Hospital Authority (QoC HDPPP)
Evaluation of Quality of Care - Haemodialysis Public-Private-Partnership, Hospital Authority (HA)
Patients with end-stage renal failure (ESRF) have lost the function to excrete urea and maintain electrolyte balance, which is lethal unless they are given renal replacement therapy (Gibney, Hoste et al. 2008). As one of the initiatives of service improvement, the HA has introduced the haemodialysis public-private partnership (HD PPP) programme to shorten the waiting time for patients with ESRF needing HD treatment. HD PPP programme is a new service provision model that purchases healthcare services from non-Government healthcare organizations. The evaluation on the quality of care (QOC) is an essential part of the programme in order to inform future policy. The Department of Family Medicine and Primary Care of the University of Hong Kong has been appointed by the HA to carry out the evaluation of the QOC of the programme.
The Action Learning and Audit Spiral methodologies to measure whether the target standard of care intended by the HD PPP programme is achieved. Each HD PPP participating hospitals and centers will be invited to complete a structure evaluation questionnaire. Sixty patients who have agreed to join HD PPP and 60 control patients who have refused to take part in HD PPP will be included. The participants will be followed up by telephone to evaluate the effect of the programme on quality of life (QOL), patient enablement, and global rating of change in health condition. Data on the process of care and clinical outcomes of care will be retrieved from the HA medical records.
Main Outcome Measures: The primary outcomes are the proportion of participants who have received the planned process of care and adequate haemodialysis (HD) measured by the Kt/V
Data Analysis: Descriptive statistics on proportions meeting the QOC criteria will be calculated. The outcomes of HD PPP subjects will be compared at 6, 12, 24, 36 and 48 months by paired sample t-test. The outcomes between HD PPP subjects and control group will be compared by independent sample t-test or Chi-square test.
Results: The QOC of the HD PPP programme will be determined. Areas of deficiency and possible areas for quality enhancement will be identified.
Conclusion: The results of this study will provide empirical evidence on whether the HD PPP can achieve equivalent QOC as the usual HA care in order to guide service planning and policy decision making for patients with ESRF.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Hong Kong Island, Hongkong
- The University of Hong Kong
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Patients currently being followed up at the HA on haemodialysis, peritoneal dialysis, or are new ESRF cases will be recruited.
Exclusion Criteria:
- Patients who do not have a good vascular access, are not hemodynamically stable for HD, are not mentally sound, ambulatory and independent, are unable to understand and communicate in Chinese language, or refuse to give consent will be excluded from the HD PPP programme.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
---|
End-stage renal failure (ESRF)
end-stage renal failure (ESRF)
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
The proportion of centers that have satisfied each of the set structure criteria.
Časové okno: Five years
|
Interim analysis will evaluate in October, 2010; October, 2011; October, 2012; October, 2013; October, 2014
|
Five years
|
The proportion of patients who have complied with the HD PPP process of care.
Časové okno: Five years
|
Interim analysis will evaluate in June, 2011; December, 2011; December, 2012; December, 2013; December, 2014
|
Five years
|
The proportion of patients who have adequate HD measured by the Kt/V.
Časové okno: Five years
|
Interim analysis will evaluate in June, 2011; December, 2011, December, 2012; December, 2013; December, 2014
|
Five years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Clinical outcomes include decompensation episodes, pre-dialysis serum calcium level, blood pressure (BP), LDL-C, patient mortality and adverse clinical events.
Časové okno: Five years
|
Baseline, 6, 12, 24, 36, 48 months after enrolment
|
Five years
|
Patient reported outcomes (PRO) are measured by the change in Short Form -12v2 scores, the Patient ennoblement index and Global Rating of Change Scale scores
Časové okno: Five years
|
Baseline and 6-month/12-month/24-month/36-month after the first administration of questionnaire.
|
Five years
|
Service utilization outcomes are measured by General Out-patient Clinics consultation, renal Specialist Out-patient Clinics consultation, A&E attendance rates and hospitalization rate in the past 12 months.
Časové okno: Five years
|
Baseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 5 years.
|
Five years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Cindy L.K. Lam, MD, Department of Family Medicine and Primary Care, Faculty of Medicine, The University of Hong Kong
- Vrchní vyšetřovatel: Julie Chen, MD, Department of Family Medicine and Primary Care, Faculity of Medicine, The University of Hong Kong
Publikace a užitečné odkazy
Obecné publikace
- Wan EY, Chen JY, Choi EP, Wong CK, Chan AK, Chan KH, Lam CL. Patterns of health-related quality of life and associated factors in Chinese patients undergoing haemodialysis. Health Qual Life Outcomes. 2015 Jul 29;13:108. doi: 10.1186/s12955-015-0308-3.
- Chen JY, Choi EP, Wan EY, Chan AK, Tsang JP, Chan KH, Lo WK, Lui SL, Chu WL, Lam CL. Validation of the Disease-Specific Components of the Kidney Disease Quality of Life-36 (KDQOL-36) in Chinese Patients Undergoing Maintenance Dialysis. PLoS One. 2016 May 5;11(5):e0155188. doi: 10.1371/journal.pone.0155188. eCollection 2016.
- Chen JY, Wan EY, Chan KH, Chan AK, Chan FW, Lam CL. Evaluation of the quality of care of a haemodialysis public-private partnership programme for patients with end-stage renal disease. BMC Nephrol. 2016 Jul 11;17(1):79. doi: 10.1186/s12882-016-0284-9.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- HKCTR-1188
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na End-stage Renal Failure (ESRF)
-
National Taiwan University HospitalNeznámý
-
Hospices Civils de LyonDokončenoEnd-stage Renal Disease (ESRD)Francie
-
Ottawa Hospital Research InstituteHeart and Stroke Foundation of OntarioDokončenoEnd-stage Renal Disease (ESRD) | Nemoc ledvinKanada
-
Ionis Pharmaceuticals, Inc.BayerDokončenoEnd-stage Renal Disease (ESRD)Kanada
-
Epizon Pharma, Inc.DokončenoEnd-stage Renal Disease (ESRD)Spojené státy
-
Rockwell Medical Technologies, Inc.DokončenoEnd-stage Renal Disease (ESRD)Spojené státy, Kanada
-
Ionis Pharmaceuticals, Inc.BayerDokončenoEnd-stage Renal Disease (ESRD)Španělsko
-
Baxter Healthcare CorporationGambro Dialysatoren GmbHDokončenoEnd-stage Renal Disease (ESRD)Itálie
-
University of Kansas Medical CenterDokončenoEnd-stage Renal Disease (ESRD) | Chronické onemocnění ledvin (CKD)Spojené státy
-
Lundquist Institute for Biomedical Innovation at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Davita...NeznámýChronické onemocnění ledvin (CKD) | End-stage Renal Disease (ESRD)Spojené státy